Infection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age.
6 affiliations
- 1Department of Neurology, Akershus University Hospital, Norway.
- 2Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
- 3Norwegian MS Registry and Biobank, Departtment of Neurology, Haukeland University Hospital, Bergen, Norway.
- 4Department of Neurology, Neuro-SysMed, Haukeland University Hospital, Bergen, Norway.
- 5Department of Clinical Medicine, University of Bergen, Norway; and.
- 6Department of Clinical Medicine, University of Oslo, Norway.
Abstract
Background and objectives
Rituximab is the most frequently used disease-modifying therapy in multiple sclerosis (MS) in Norway. Extended dosing intervals beyond 6 months may offer the same efficacy, but the impact on infection risk is unclear. We examined how dosing frequency and age affect infection risk in rituximab-treated patients with MS.Methods
We conducted a nation-wide observational study linking compulsory Norwegian health registries with the Norwegian MS registry. Registry data captured hospital-treated infections and further infections requiring prescription treatment and/or physician contact with primary practice. Data were analyzed using the Prentice, Williams, and Peterson model with clustering on subject to account for longitudinal design, recurrent rituximab infusions and recurrent infection events while adjusting for relevant explanatory variables. Rituximab interval length was modelled as the number of rituximab infusions within 2 years. Age was grouped into 5-year intervals.Results
Among 3,410 patients (13,811 treatment episodes between 2010 and June 2022), 13,774 infections occurred, including 971 hospital-treated events. Compared with 4 infusions over 2 years (6-month intervals), extended dosing was associated with a lower risk of any infection (hazard ratio [HR] 0.90 [95% CI 0.82-0.99]) for 2 infusions; (HR 0.78 [95% CI 0.69-0.88] for 1 infusion). A reduced risk of hospital-treated infections was observed only for 1 infusion per 2 years relative to 4, and this was not robust in sensitivity analyses and not present for the subgroup of infections associated with overnight hospital stay. Patients ≥60 years had a significantly higher risk of hospital-treated infections (HR 1.36 [95% CI 1.07-1.71]).Discussion
Extended rituximab intervals are associated with reduced overall infection risk, but the benefit for hospital-treated infections is limited. Age ≥60 years independently increases the risk of hospital-treated infections. These findings support cautious interval extension and careful risk-benefit assessment in older patients.
Related
- Rituximab and Ocrelizumab in Multiple Sclerosis: Does Comparative Evidence Redefine Anti-CD20 Therapy?
- Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy.
- Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
- Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis
- Disseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series.
BibTeX
@article{pihljensen2026infection,
title = {{Infection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age.}},
author = {Gorm Pihl-Jensen and Maria Lie Selle and Jan Harald Aarseth and Kjell-Morten Myhr and Øivind Torkildsen and Ola Nakken and Trygve Holmøy},
journal = {Neurology. Clinical practice},
year = {2026},
month = oct,
doi = {10.1212/cpj.0000000000200664},
url = {https://europepmc.org/article/MED/42854181},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Infection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age.
AU - Gorm Pihl-Jensen
AU - Maria Lie Selle
AU - Jan Harald Aarseth
AU - Kjell-Morten Myhr
AU - Øivind Torkildsen
AU - Ola Nakken
AU - Trygve Holmøy
PY - 2026
DA - 2026/10/08
JO - Neurology. Clinical practice
DO - 10.1212/cpj.0000000000200664
UR - https://europepmc.org/article/MED/42854181
AB - Background and objectives Rituximab is the most frequently used disease-modifying therapy in multiple sclerosis (MS) in Norway. Extended dosing intervals beyond 6 months may offer the same efficacy, but the impact on infection risk is unclear. We examined how dosing frequency and age affect infection risk in rituximab-treated patients with MS.Methods We conducted a nation-wide observational study linking compulsory Norwegian health registries with the Norwegian MS registry. Registry data captured hospital-treated infections and further infections requiring prescription treatment and/or physician contact with primary practice. Data were analyzed using the Prentice, Williams, and Peterson model with clustering on subject to account for longitudinal design, recurrent rituximab infusions and recurrent infection events while adjusting for relevant explanatory variables. Rituximab interval length was modelled as the number of rituximab infusions within 2 years. Age was grouped into 5-year intervals.Results Among 3,410 patients (13,811 treatment episodes between 2010 and June 2022), 13,774 infections occurred, including 971 hospital-treated events. Compared with 4 infusions over 2 years (6-month intervals), extended dosing was associated with a lower risk of any infection (hazard ratio [HR] 0.90 [95% CI 0.82-0.99]) for 2 infusions; (HR 0.78 [95% CI 0.69-0.88] for 1 infusion). A reduced risk of hospital-treated infections was observed only for 1 infusion per 2 years relative to 4, and this was not robust in sensitivity analyses and not present for the subgroup of infections associated with overnight hospital stay. Patients ≥60 years had a significantly higher risk of hospital-treated infections (HR 1.36 [95% CI 1.07-1.71]).Discussion Extended rituximab intervals are associated with reduced overall infection risk, but the benefit for hospital-treated infections is limited. Age ≥60 years independently increases the risk of hospital-treated infections. These findings support cautious interval extension and careful risk-benefit assessment in older patients.
SN - 2163-0402
SN - 2163-0933
ER -